Patricia S. Andrews has served as a director of Geron since March 2026. Ms. Andrews also serves as a member of the Board of Directors of Glenmark Pharmaceuticals Limited, a global pharmaceutical company, and as a director of its wholly-owned subsidiary, Ichnos Glenmark Innovation (IGI), a clinical-stage oncology research and development company, positions she has held since August 2025. She has served as a member of the Board of Directors of Oncolytics Biotech Inc., a clinical-stage oncology company, since January 2024. She previously served as a member of the Board of Directors and as a member of the Audit Committee of GlycoMimetics, Inc., a clinical-stage biopharmaceutical company focused on oncology, from June 2017 until June 2025, when GlycoMimetics was combined with Crescent Biopharma. Ms. Andrews served as Chief Executive Officer of Sumitomo Pharma Oncology, Inc. (formerly Boston Biomedical, Inc.), a clinical-stage biopharmaceutical company focused on the treatment of hematological malignancies and solid tumors, and as an Executive Officer of its parent company, Sumitomo Pharma Co., Ltd., from April 2017 to June 2023. Ms. Andrews was also the Global Head of Oncology for Sumitomo Pharma Co., Ltd. from June 2020 to June 2023. Prior to her appointment as Chief Executive Officer, Ms. Andrews joined Boston Biomedical in November 2013 as Executive Vice President and Chief Commercial Officer, and was promoted to Chief Operating Officer in 2015 before assuming the chief executive role. Prior to joining Sumitomo Pharma Oncology and its predecessor, Ms. Andrews served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from October 2008 to August 2012. Prior to Incyte, Ms. Andrews held roles of increasing responsibility at Pfizer Inc. from 1991 to 2008, including as Vice President and General Manager of the U.S. Oncology Business Unit and Vice President, Specialty Markets. Ms. Andrews holds an M.B.A. with a focus on Finance from the University of Michigan (Ann Arbor) and a B.A. in History and Political Science from Brown University. THE BOARD BELIEVES MS. ANDREWS' EXTENSIVE EXPERIENCE AS AN EXECUTIVE OFFICER IN ONCOLOGY-FOCUSED BIOPHARMACEUTICAL ORGANIZATIONS, HER EXPERTISE IN BUILDING AND LEADING COMMERCIAL OPERATIONS AND EXECUTING MAJOR LICENSING TRANSACTIONS, AS WELL AS HER KNOWLEDGE OF DRUG DEVELOPMENT, CLINICAL TRIAL MANAGEMENT, AND HEALTHCARE-RELATED ISSUES, COMBINED WITH HER EXPERIENCE AS A DIRECTOR OF MULTIPLE PUBLICLY TRADED BIOPHARMACEUTICAL COMPANIES, PROVIDES GREAT VALUE TO THE BOARD AND QUALIFIES HER TO BE ELECTED AS A DIRECTOR.